Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11824888 | 0.91 | SIGMAR1 (0.52) | HTR1ADRD2HTR2ASIGMAR1PPARG | |
| SCHEMBL11839372 | 0.89 | HTR1A (0.52) | HTR1ADRD2HTR2ASIGMAR1MAPT | |
| SCHEMBL4763284 | 0.84 | HTR1A (0.44) | HTR1ADRD2HTR2ASIGMAR1MAPT | |
| SCHEMBL4763276 | 0.84 | HTR1A (0.44) | HTR1ADRD2HTR2ASIGMAR1MAPT | |
| SCHEMBL7213708 | 0.80 | HTR1D (0.54) | HTR1ADRD2HTR2ALMNAKDM4E | |
| SCHEMBL7216009 | 0.79 | DRD2 (0.43) | HTR1ADRD2HTR2ASIGMAR1 | |
| SCHEMBL7220005 | 0.79 | DRD2 (0.46) | HTR1ADRD2HTR2ALMNAKDM4E | |
| SCHEMBL7215914 | 0.79 | HTR1A (0.45) | HTR1ADRD2HTR2ASIGMAR1LMNA | |
| SCHEMBL6794572 | 0.78 | DRD2 (0.59) | HTR1ADRD2HTR2AMAPTNOTUM | |
| SCHEMBL5398831 | 0.78 | HTR1D (0.54) | HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044007-A1 | Indoline derivatives | H. LUNDBECK A/S (DK) | 2004-03-04 | — | — | US | claimed |
| EP-1345921-A1 | 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS | H. Lundbeck A/S (DK) | 2003-09-24 | — | — | EP | claimed |
| WO-2002051833-A1 | 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS | H. LUNDBECK A/S (DK) | 2002-07-04 | — | — | WO | claimed |
| EP-1345921-A1 | 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS | H. Lundbeck A/S (DK) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051833-A1 | 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS | H. LUNDBECK A/S (DK) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044007-A1 | Indoline derivatives | CNR1, GRIN2C, HTR3C | HTR1A 7/4885DRD2 43/4885HTR2A 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.